Clinical Trial Update: Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating the addition of immune therapies Tocilizumab and Atezolizumab to radiation therapy for recurrent glioblastoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Astrocytoma Idh-wildtype
• Glioblastoma Recurrent

Drugs mentioned

• Actemra (tocilizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING